期刊文献+

AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma 被引量:17

AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma
下载PDF
导出
摘要 BACKGROUND: In liver transplantation or resection for hepatocellular carcinoma (HCC), patient selection depends on morphological features. In patients with HCC, we performed a clinicopathological analysis of risk factors that affected survival after liver transplantation. METHODS: In 389 liver transplantations performed from 2004 to 2010, 102 were for HCC patients. Data were collected retrospectively from the Organ Transplantation Center Database. Variables were as follows: age, gender, preoperative alpha-fetoprotein (AFP) levels, Child-Pugh and MELD scores, prognostic staging criteria (Milan and UCSF), etiology, number of tumors, the largest tumor size, total tumor size, multifocality, intrahepatic portal vein tumor thrombosis, bilobarity, and histological differentiation. RESULTS: One hundred and two patients were evaluated. The 5-year overall survival rate was 56.5%. According to the UCSF criteria, 63% of the patients were within and 37% were beyond UCSF (P=0.03). Ten patients were excluded (one with fibrolamellary HCC and 9 because of early postoperative death without HCC recurrence), and 92 patients were assessed. The mean age of the patients was 56.5±6.9 years. Sixty-two patients underwent living donor liver transplantations. The mean follow-up time was 29.4±22.6 months. Fifteen patients (16.3%) died in the follow-up period due to HCC recurrence. Univariate analysis showed that AFP level, intrahepatic portal vein tumor thrombosis, histologic differentiation and UCSF criteria were significant factors related to survival and tumor recurrence. The 5-year estimated overall survival rate was 62.2% in allpatients. According to the UCSF criteria, and the 5-year overall survival rate was 66.7% within and 52.7% beyond the criteria (P=0.04). Multivariate analysis showed that AFP level and poor differentiation were independent factors. CONCLUSIONS: For proper patient selection in liver trans- plantation for HCC, prognostic criteria related to tumor biology (especially AFP level and histological differentiation) should be considered. Poor differentiation and higher AFP levels are indicators of poor prognosis after liver transplantation. BACKGROUND: In liver transplantation or resection for hepatocellular carcinoma (HCC), patient selection depends on morphological features. In patients with HCC, we performed a clinicopathological analysis of risk factors that affected survival after liver transplantation. METHODS: In 389 liver transplantations performed from 2004 to 2010, 102 were for HCC patients. Data were collected retrospectively from the Organ Transplantation Center Database. Variables were as follows: age, gender, preoperative alpha-fetoprotein (AFP) levels, Child-Pugh and MELD scores, prognostic staging criteria (Milan and UCSF), etiology, number of tumors, the largest tumor size, total tumor size, multifocality, intrahepatic portal vein tumor thrombosis, bilobarity, and histological differentiation. RESULTS: One hundred and two patients were evaluated. The 5-year overall survival rate was 56.5%. According to the UCSF criteria, 63% of the patients were within and 37% were beyond UCSF (P=0.03). Ten patients were excluded (one with fibrolamellary HCC and 9 because of early postoperative death without HCC recurrence), and 92 patients were assessed. The mean age of the patients was 56.5±6.9 years. Sixty-two patients underwent living donor liver transplantations. The mean follow-up time was 29.4±22.6 months. Fifteen patients (16.3%) died in the follow-up period due to HCC recurrence. Univariate analysis showed that AFP level, intrahepatic portal vein tumor thrombosis, histologic differentiation and UCSF criteria were significant factors related to survival and tumor recurrence. The 5-year estimated overall survival rate was 62.2% in allpatients. According to the UCSF criteria, and the 5-year overall survival rate was 66.7% within and 52.7% beyond the criteria (P=0.04). Multivariate analysis showed that AFP level and poor differentiation were independent factors. CONCLUSIONS: For proper patient selection in liver trans- plantation for HCC, prognostic criteria related to tumor biology (especially AFP level and histological differentiation) should be considered. Poor differentiation and higher AFP levels are indicators of poor prognosis after liver transplantation.
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2012年第3期256-261,共6页 国际肝胆胰疾病杂志(英文版)
关键词 liver transplantation hepatocellular carcinoma ALPHA-FETOPROTEIN liver transplantation hepatocellular carcinoma alpha-fetoprotein
  • 相关文献

参考文献27

  • 1A Taketomi,K Sanefuji,Y Soejima,T Yoshizumi,H Uhciyama,T Ikegami.Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation . 2009
  • 2S Todo,H Furukawa,M Tada.Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transplantation . 2007
  • 3SG Lee,S Hwang,DB Moon,CS Ahn,KH Kim,KB Sung,GY Ko,KM Park,TY Ha,GW Song.Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transplantation . 2008
  • 4Zheng SS,Xu X,Wu J,Chen J,Wang WL,Zhang M,et al.Liver transplantation for hepatocellular carcinoma:Hangzhou experiences. Transplantation . 2008
  • 5M Fujiki,Y Takada,Y Ogura,F Oike,T Kaido,S Teramukai,S Uemoto.Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation or hepatocellular carcinoma. American Journal of Transplantation . 2009
  • 6EA Pomfret,K Washburn,C Wald,MA Nalesnik,D Douglas,M Russo.Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplantation . 2010
  • 7J. Bruix,M. Sherman.Management of hepatocellular carcinoma: an update. Hepatology . 2011
  • 8El-Serag HB,,Marrero JA,Rudolph L,Reddy KR.Diagnosis and treatment of hepatocellularcarcinoma. Gastroenterology . 2008
  • 9Shariff MI,Cox IJ,Gomaa AI,Khan SA,Gedroyc W,Taylor-Robinson SD.Hepatocellular carcinoma:current trends in worldwide epidemiology,risk factors,diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol . 2009
  • 10R Wong,C Frenette.Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol N Y . 2011

共引文献24

同被引文献130

引证文献17

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部